1McLENNAN S, FISHER E, MARTELL S Y, et al. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy [ J ].Kideny Int,2000,58( Suppl 77) :S81-87.
2MIGNATFI P. Extracellular matrix remodeling by metalloproteinases and plasminogen activators [ J ]. Kidney Int, 1995,47( Suppl 49) : S12-14.
3MURPHY G, KNAUPER V, COWELL S. Evaluation of some newer matrix metalloproteinases [ J]. Ann N Y Acad Sci,1999, 878:25 -39.
4KUGLER A. Matrix metalloproteinasws and their inhibitors[ J ]. Anticancer Res, 1999,19 : 1589-1592.
5VU T H, WERB Z. Matrix metalloproteinases: effectors of development and normal physiology [ J ]. Genes Dev, 2000,14 :2123-2133.
6BODE W, FERNANDEZ-CATALAN C, GRAMS F, et al. Insights into MMP-TIMP interactions [ J]. Ann N Y Acad Sci, 1999,878:73-91.
7WU K,SETYY S, MAUER S M,et al. Altered kidney matrix gene expression in early stages of experimental diabetes [ J ].Acta Anat Basel, 1997,158 : 155-165.
8EBIHARA L J,NAKAMURA T,SHIMADA N,et al. Increased plasma metalloproteinase 9 concentrations precede development of microalbuminuria in non insulin dependent diabetes mellitus[J]. Am J Kideny Dis,1998,32:544-550.
9TASHIRO K, KOYANAGI I,OHARA I,et al. Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy [ J ]. J Clin Lab Anal,2004,18(3) :206-210.
10GIUSEPPE D, MARIA A A, DIEGO G, et al. Matrix Metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes [ J ]. Diabetes Care,2004,27:273 -274.
2D. Del Prete,F. Anglani,M. Forino,M. Ceol,P. Fioretto,R. Nosadini,B. Baggio,G. Gambaro. Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM[J] 1997,Diabetologia(12):1449～1454
3Ferroni P,Basili S,Hoyhtya M,et al.Serum metallo-proteinase9 levels In patients with coronary artery disease,a novel marker of inflammation[J].Invest Med,2003,51:295-300.
4Aslanian AM,Oharo IF.Targeted disruption of the scavenger receptor and chemokine CXC-L16 accelerates atherosclerosis[J].Circulation,2006,114(6):583-590.
5Meuwissen M,van der Wal AC,Niessen HW,et al.Colocalisation of intraplaque C reactive protein,complement,oxidised low density lipoprotein,and macrophages in stable and unstabe angina and acute myocardial infarction[J].J Olin pathol,2006,59(2):196-201.
6Ohen WQ,Zhang M,Ji XP,et al.Usefulness of high-frequency vascular ultrasound Imaging and serum inflammatory markers to predict plaque rupture in patients with stable and Unstable angina pectoris[J].Am J Cardiol,2007,100(9):1341-1346.
7Russell DA,Abbott CR,Gough MJ.Vascular endothelial growth factor is associated with histological instability of carotid plaques[J].Br J Surg,2006,95(5):576-588.
8DOO Y C,HAN S J,HAN S W,et al.Effect of preexisting statin use on expression of C-reactive protein,adhesion molecules,inter-leukin26,and antioxidized low-density lipoprotein antibody in patients with unstable angina undergoing coronary stenting[J].Clin Cardiol,2005,26(2):72-76.
9Planavila A,Laguna JO,Vazquez-Oarrera M.Atorvastatin improves peroxisome proliferators-activated receptor signaling in cardiac hypertrophyby preventing nuclear factor-kappa B activation.Biochim Biophys Acta,2005,Vol.1687(1-3):76-83.
10Festa A D, Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atheroscterosis Study (IRAS)[J]. Circulation. 2000, 102 ( 1 ) : 42-47.
